Obstetrics & Gynecology, Gynecology · Lexington, KY
NPI
1215916044
Since 2006
Specialty
Obstetrics & Gynecology, Gynecology
Code 207VG0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1720 Nicholasville Rd Ste 702
Lexington, KY, 40503
Phone (859) 264-8811
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
766 services
Medicare patients, 2024
393
Average age 72
Drug cost, 2024
$99K
1,574 prescriptions
Company payments, 2025
$171
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Reva D Tackett was code G0101 (cervical or vaginal cancer screening; pelvic and clinical breast examination), 181 times for 181 patients. In total Reva D Tackett billed 766 services in 17 codes, and Medicare paid $30K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-03.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| G0101 Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 181 | 181 | $35.52 | $6,429 |
| 99213 Office E&M - Established | Office | 175 | 147 | $53.67 | $9,392 |
| 99212 Office E&M - Established | Office | 143 | 118 | $35.56 | $5,085 |
| Q0091 Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 137 | 137 | $39.43 | $5,402 |
| 99459 Office/Outpatient Services | Office | 64 | 57 | $13.08 | $837 |
| 81003 Clinical Chemistry | Office | 16 | 14 | $2.20 | $35.2 |
| 99214 Office E&M - Established | Office | 13 | 12 | $71.68 | $932 |
By year: 2022 $29K for 606 services; 2023 $26K for 607 services; 2024 $30K for 766 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 16 | 14 | $2.20 | $35.2 |
Medicare prescription drug claims, 2024
In 2024, the drug Reva D Tackett prescribed most often to Medicare patients was Estradiol, with 294 prescriptions and refills. In total Reva D Tackett wrote 1,574 Medicare prescriptions that cost $99K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Estradiol Generic | 294 | 816 | 118 | $16K |
| Estradiol (Twice Weekly) Estradiol | 114 | 220 | 30 | $12K |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 95 | 99 | 69 | $1,462 |
| Valacyclovir Valacyclovir Hcl | 81 | 126 | 26 | $2,028 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 75 | 143 | 25 | $1,351 |
| Raloxifene Hcl Generic | 74 | 184 | 19 | $3,743 |
| Fluconazole Generic | 70 | 70 | 43 | $300 |
| Medroxyprogesterone Acetate Generic | 53 | 129 | 13 | $601 |
| Estradiol (Once Weekly) Estradiol | 48 | 106 | 13 | $5,188 |
| Progesterone Progesterone, Micronized | 38 | 86 | Under 11 | $1,493 |
| Levothyroxine Sodium Generic | 34 | 94 | Under 11 | $418 |
| Cefuroxime Cefuroxime Axetil | 29 | 29 | 23 | $318 |
| Citalopram Hbr Citalopram Hydrobromide | 29 | 83 | Under 11 | $164 |
| Clobetasol Propionate Generic | 28 | 35 | 16 | $1,338 |
| Dotti Estradiol | 28 | 57 | Under 11 | $3,876 |
Brand drugs: 180 claims; generic drugs: 1,380 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Reva D Tackett $171 ($171 in general payments such as food, travel and fees) from 9 companies. The largest payer was Mayne Pharma Commercial LLC with $30.99.
| Company | Payments | Amount |
|---|---|---|
| Mayne Pharma Commercial LLC | 3 | $30.99 |
| Astellas Pharma US Inc 4503.T | 1 | $22.5 |
| Hologic Sales and Service, LLC HOLX | 1 | $20.45 |
| Millicent US Inc | 1 | $17.26 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $16.9 |
| Sage Therapeutics, LLC SAGE | 1 | $16.26 |
| Novo Nordisk Inc NVO | 1 | $16.03 |
| Lilly USA, LLC LLY | 1 | $15.31 |
| Exact Sciences Corporation EXAS | 1 | $15.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.